

AD _____

Award Number: DAMD17-98-1-8083

TITLE: Breast Cancer Biomarkers Based on Nipple and Fine Needle Aspirates

PRINCIPAL INVESTIGATOR: Irma H. Russo, M.D.

CONTRACTING ORGANIZATION: Fox Chase Cancer Center
Philadelphia, PA 19111

REPORT DATE: May 2005

TYPE OF REPORT: Final

20060307 091

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE (DD-MM-YYYY) 01-05-2005		2. REPORT TYPE Final		3. DATES COVERED (From - To) 1 May 1998 - 30 Apr 2005	
4. TITLE AND SUBTITLE Breast Cancer Biomarkers Based on Nipple and Fine Needle Aspirates				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER DAMD17-98-1-8083	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Irma H. Russo, M.D. E-Mail: irma.russo@fccc.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Fox Chase Cancer Center Philadelphia, PA 19111				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Abstract follows.					
15. SUBJECT TERMS Breast cancer risk, molecular biomarkers, BRCA1, BRCA2, genomic analysis, differentiation, cDNA array, ductal lavage, nipple aspirate fluid					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 14	19a. NAME OF RESPONSIBLE PERSON
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

ABSTRACT

Women who are carriers of inherited germline mutations have an 85% lifetime risk of developing breast cancer. BRCA1 carriers are more likely to develop tumors at an earlier age that are estrogen receptor negative, therefore they cannot benefit from antiestrogen chemopreventive treatments. Because currently it is not possible to predict who will actually develop breast cancer, we have designed studies using molecular approaches for identifying the "high risk" genomic signature of the cytological normal breast epithelium of women at high risk for breast cancer. This signature will serve as an intermediate biomarker for evaluating the response of the breast to novel chemopreventive agents. We performed cDNA microarray analysis of pure epithelial cell populations obtained by laser capture microdissection (LCM) from cytological smears of the normal human breast epithelial cell line MCF-10F. Our observations confirmed the usefulness of combining LCM and cytospin preparations for obtaining pure cell populations for RNA extraction, and of PCR RNA amplification for cDNA microarray analysis and quantification of gene expression level by real time RT-PCR. These studies will lead to fruitful results through genomic hierarchical cluster analysis and Bioinformatics for patient risk assessment and for evaluating the responsiveness of the breast epithelium to chemopreventive agents.

Table of Contents

Front Cover	
Standard Form 298	
Table of Contents	3
Introduction	4
Body	4
Key Research Accomplishments	8
Reportable Outcomes	8
Conclusions	8
References	8
List of Personnel	12
Appendices	12

Introduction

Breast cancer, the most frequently diagnosed malignant disease in American and Northern European women of all ethnic groups, is continually increasing in incidence in most industrialized countries (1-3). Early detection and improved treatment modalities have succeeded in reducing breast cancer mortality rates in the United States by 2.3% per year since 1990 (3,4). However, it is fatal once it metastasizes, remaining as the number one cause of cancer-related death in non-smokers (1). Although the cause of the disease and of the worldwide increase in incidence remains largely unknown, the main risk factors that predispose the breast to malignancy have been clearly identified to be endogenous, namely, being of female sex, having a functional ovary cyclically secreting estrogens, exhibiting specific endocrinological conditions, such as early menarche, late menopause, and nulliparity (5-7), and being carriers of inherited germline mutations (8-10). The risk of these populations is further increased by exposure to environmental factors such as radiation (11,12), circadian disruption acting as endocrine disrupter (13,14), smoking (15,16), and alcohol consumption (17). Among the endogenous factors, the inheritance of germline mutations in the *BRCA1* or *BRCA2* genes is low in frequency, affecting less than 5% of the female population (8-10). However, it represents a definitive threat, since women that are carriers of these mutations are at an 85% lifetime risk of developing breast cancer. The disease is also diagnosed at a significantly younger age than sporadic breast cancer, and the tumors, especially in women carriers of the mutant *BRCA1*, are more aggressive and generally negative for estrogen (ER) and progesterone (PR) receptors, therefore they cannot reap the benefits of antiestrogen preventive and therapeutic modalities (18-20). Thus, the only preventive measure available to this high-risk population is prophylactic mastectomy (10,20). This dismal picture emphasizes the need of preventing this disease as the ultimate approach for its control. Recent progress in defining the early premalignant phases of breast cancer and the development of molecular tools have provided novel biomarkers that will contribute to making primary prevention a real possibility (21). The identification in preclinical studies that mammary cancer is prevented if the mammary gland becomes differentiated prior to its exposure to a carcinogenic agent (22-32) led us to postulate that hormonally induced differentiation is the most physiological approach for the prevention of cancer in women. Towards this goal we have designed experiments for determining whether the protection conferred by the hormones of pregnancy and more specifically, human chorionic gonadotropin (hCG) protect the mammary gland through the induction of a specific genomic signature that characterizes the differentiated mammary gland (33,34). This signature, in turn, would serve as an intermediate biomarker for assessing the response of the mammary gland to specific hormonal stimuli and as a predictor of resistance to neoplastic transformation.

Body

We have demonstrated that RNA extracted from the mammary gland of virgin Sprague-Dawley rats that have received a daily intraperitoneal injection of 100 IU/hCG for 21 days after analysis employing an oligonucleotide microarray provides a gene expression profile that is characteristic for this hormone. The genomic signature induced by hCG is similar to that induced by pregnancy, and is characterized by upregulation of genes that are *activators or repressors of transcription*, i.e., CREB1, p21, and GADD153, *apoptosis*; i.e., caspase 1; *growth factors*, i.e.,

TGF-beta3; *cell division control*, i.e. p21 Cdk 1 inhibitor; *DNA repair genes*, i.e., GADD153 and Casein kinase delta; *tumor suppressor genes*, i.e., p53, *Cell-surface antigens*, i.e., B7.1, CD-28, and CD44 antigen. The levels of gene expression have been validated by real time RT-PCR, confirming that the mammary glands of hCG-treated virgin rats and of parous rats, which are resistant to chemically induced carcinogenesis, exhibit permanent genomic changes that serve as intermediate biomarkers of cancer prevention (33-35).

Our studies have further demonstrated that hCG treatment of rats previously exposed to DMBA inhibits the progression of preneoplastic lesions, such as intraductal proliferations and carcinomas in situ (29,35-39). This indication of a direct effect of hCG on the mammary epithelium has been further confirmed by *in vitro* hCG treatment of MCF-10 and MCF-7 cells, normal and neoplastic breast epithelial cell lines respectively. In these cells, hCG inhibits growth, depresses cell proliferation, lengthens the G1 phase of the cell cycle, and induces the synthesis of α and β inhibin, a non-steroidal glycoprotein belonging to the TGB- β family with demonstrated tumor suppressor activity (40,41). These observations indicate that hCG acts both through ovarian stimulation and directly on individual mammary cells to inhibit cancer cell growth by activating an autocrine/paracrine loop mediated by inhibin.

Based on the strength of the preclinical data described above, a pilot clinical trial was conducted to determine whether hCG administered to breast cancer patients would induce in the tumors the same biomarkers identified in the rodent mammary cancers and that are indicators of cancer regression (42). Twenty-five postmenopausal women with palpable primary breast cancers >1.5 cm were eligible. After confirmation of the diagnosis by core biopsy, patients were randomized to receive 500 μ g of recombinant human chorionic gonadotropin (r-hCG) by intramuscular injection every other day times seven, or saline placebo. At the completion of the study treatment, all patients underwent mastectomy. Pre- and post-treatment tumor specimens were examined for rate of cell proliferation, estrogen and progesterone receptor expression, and immunoreactivity for inhibin. Treatment with r-hCG induced a statistically significant decrease in rates of cell proliferation and down regulation of ER and PR expression in tumor cells. At the same time, a significant increase in immunoreactivity for inhibin was observed in the neoplastic cells. No systemic changes in ovarian steroid or pituitary hormones were observed, suggesting that the effects of hCG are organ specific (42). Thus, our experimental *in vitro* and *in vivo* systems have demonstrated that hCG exerts both a preventive effects by inducing a specific genomic signature as result of mammary gland differentiation that prevents the initiation of chemically-induced mammary carcinomas and the induction of differentiation of chemically transformed cells, inhibiting the progression of mammary carcinomas.

Human chorionic gonadotropin (hCG) has been used clinically for many years for the treatment of male and female infertility, corpus luteum insufficiency, habitual or threatened abortion, hypogonadism and cryptorchidism in the male, and weight reduction (43-45). It is well tolerated without significant toxicities and therefore offers enormous promise as a chemopreventive agent for women with a familial/genetic risk for breast cancer. However, the inability to predict in this high risk population who will develop breast cancer has required the implementation of broad, population-based strategies utilizing preventive measures that have significant side effects and require protracted treatment. Therefore, we are addressing the need of precisely identifying those women who should take a preventive agent, sparing others who will not develop the disease

during their lifetimes. It is in this status of knowledge that we have developed a new paradigm for breast cancer prevention, the identification of the genomic and proteomic signatures that characterize the breast at high risk. The accomplishment of this goal became feasible due to the combination of nipple fluid aspirate (NFA) with the more recently developed ductal lavage (46-49), a noninvasive procedure that yields both cellular and non-cellular material for evaluation. Cellular and breast fluids obtained using these methodologies provide material adequate for analysis utilizing high-throughput microarray (50,51) and proteomic technologies (52-54). The selection of pure epithelial cell populations by laser capture microdissection (LCM) allows researchers the amplification of RNA from well characterized cells in which cytopathological and immunocytochemical characteristics that have served as traditional biomarkers can be correlated with novel genomic and proteomic signatures. These combined technologies represent powerful tools for generating a vast amount of information on the genomic and protein profiles of the breast ductal system in a single experiment. While working under this training grant we have analyzed pure epithelial cell populations obtained by laser capture microdissection (LCM) utilizing cytological smears of the normal human breast epithelial cell line MCF-10F, a normal immortalized human breast epithelial cell line that has been maintained in our laboratory for more than 14 years (55). The first objective was the determination of the minimal number of cells that would yield adequate quantity of high quality RNA for genomic analysis.

Cell Culture: MCF-10F cells were grown in DMEM/F12 high-calcium (1.05 mM) medium at 37°C in a humidified atmosphere of 5% CO₂. When the cultures reached 80-90% of confluence, the cells were trypsinized, counted using hemacytometer and fixed in nuclease free 50% ETOH for 20 minutes.

Cytospin preparation: Cell suspensions were evenly distributed in 8 cytospin non adhesive slides and centrifuged at 1200 rpm at room temperature for 10 min. Each slide contained approximately 4.6×10^5 cells. After centrifugation slides were dried at room temperature for 2 min, sequentially followed by immersion in 75% ETOH for 30 sec, ddH₂O for 30 sec, Histostain for 20 sec, ddH₂O for 30 sec, 75% ETOH for 30 sec, 95 % ETOH for 30sec, 100% ETOH for 30 sec, xylene for 5 min, and air dried for 5 min.

Laser Capture microdissection (LCM): Three set of cells were collected in duplicate using LCM: 20, 200 and 2000 cells. LCM was performed using the AutoPix 1000 Laser capture equipment (Arcturus, CA). The microdissection conditions were: Power; 70 uV, laser diameter: 15 μ m. The cells captured were placed in nucleic lysis solution and kept on ice until processed.

RNA isolation: Total RNA from each sample was extracted with Acturus PicoPure RNA Isolation Kit. Cells were mixed with 20 ul of RNA extraction buffer and incubated at 42°C for 30 min, processing thereafter following the manufacturer's recommended procedures. All purified RNA samples were DNAsed and measured by Nanodrop and quality was assessed by Bioanalyzer 2100 (Agilent Technologies, Inc, CA) (Table 1).

RNA amplification: Two methodologies for RNA amplification were applied to each sample, Linear RNA amplification and PCR-based RNA amplification procedures. Both procedures are based on oligo-dT-T7 primer amplification followed by in vitro-transcription reaction (IVT) (Table 1).

Table 1. Total RNA extracted from MCF-10F cells after LCM

<u>MCF10F Cells Number</u>	<u>Initial Total RNA (ng)</u>	<u>Total Volume (μl)¹</u>	<u>Amplified aRNA UV260/UV280</u>	<u>Concentration (ng/μl)</u>
<u>20</u>	<u>NA</u>	<u>10</u>	<u>1.35</u>	<u>NA</u>
<u>20</u>	<u>NA</u>	<u>10</u>	<u>1.33</u>	<u>NA</u>
<u>200</u>	<u>NA</u>	<u>10</u>	<u>1.35</u>	<u>NA</u>
<u>200</u>	<u>NA</u>	<u>10</u>	<u>1.37</u>	<u>NA</u>
<u>2000</u>	<u>21</u>	<u>10</u>	<u>1.94</u>	<u>2.1</u>
<u>2000</u>	<u>65</u>	<u>10</u>	<u>1.90</u>	<u>6.5</u>

¹PicoPure Extracted TRNA with 1 μ l out of 10 μ l total RNA

RT-PCR: Real Time RT-PCR was used for validating the data obtained from each sample. The housekeeping gene 18S was utilized for generating a standard curve. Concentrations of 18S gene were compared with those of the breast epithelium specific genes fat milk globule membrane antigen and whey acidic protein (Table 2).

Table 2. 18 S RT-PCR Measurement in Total RNA

<u>MCF10F Cells Number</u>	<u>Initial Total RNA (ng)</u>	<u>Total Volume (μl)¹</u>	<u>RT-PCR Volume (μl)</u>	<u>Concentration (ng/μl)</u>
<u>20</u>	<u>0.33</u>	<u>10</u>	<u>1</u>	<u>0.033</u>
<u>20</u>	<u>0.38</u>	<u>10</u>	<u>1</u>	<u>0.038</u>
<u>200</u>	<u>0.35</u>	<u>10</u>	<u>1</u>	<u>0.035</u>
<u>200</u>	<u>0.73</u>	<u>10</u>	<u>1</u>	<u>0.073</u>
<u>2000</u>	<u>19</u>	<u>10</u>	<u>1</u>	<u>1.9</u>
<u>2000</u>	<u>53</u>	<u>10</u>	<u>1</u>	<u>5.3</u>

¹with 1 μ l out of 10 μ l total RNA

Our results led us to conclude that RT-PCR is sensitive for detecting RNA from small numbers of LCM selected cells, being able to detect few copies of RNA, whereas the amounts of RNA obtained by linear amplification did not suffice for its use in microarray analysis. These observations confirmed the usefulness of the application of LCM to cytospin preparations for obtaining pure cell populations for RNA extraction and of PCR RNA amplification for cDNA microarray analysis and of RT-PCR for gene expression level quantification. The possibilities of using a minimal number of cells and the utilization of RT-PCR instead of linear amplification for obtaining RNA in adequate amount and quality for performing cDNA microarray analysis represented a significant step to warrant that the breast epithelial cells from selected donors can

be studied in the same fashion. These studies will lead to fruitful results through genomic hierarchical cluster analysis and bioinformatics for patient risk assessment. This meeting offers a great opportunity to scientists and health care providers of discussing with consumers and the general public affected by breast cancer the potential of this approach for assessing risk using molecular biomarkers.

Key Research Accomplishments

- Confirmation of the usefulness of the application of laser capture microdissection (LCM) to cytopsin preparations for obtaining pure cell populations for RNA extraction
- Confirmation of the usefulness of RT-PCR RNA amplification for cDNA microarray analysis
- Confirmation of the usefulness of RT-PCR for gene expression level quantification.

Reportable Outcomes

This study has allowed us to confirm the possibilities of using a minimal number of cells (20) and the utilization of RT-PCR instead of linear amplification for obtaining RNA in adequate amount and quality for performing cDNA microarray analysis. This step was significantly important to warrant that the breast epithelial cells from selected donors can be studied in the same fashion.

Russo, I.H., Wang, R., Balogh, GA, Sheriff, F. Masny, A., Daly, MB, Torosian, M., Russo, J. IDENTIFICATION OF MOLECULAR BIOMARKERS OF CANCER RISK IN CYTOLOGICALLY NORMAL BREAST EPITHELIAL CELLS. Era of Hope meeting in Philadelphia, Pennsylvania, June 8-11, 2005. (attached in the appendix)

Conclusions

The goal of this application, the identification of genomic signatures that might be indicative of a high risk for cancer development of women who are carriers of BRCA/BRCA2 mutations, was accomplished through the utilization of molecular approaches for characterizing patterns of gene expression in cytologically normal breast epithelium. Our studies have confirmed the advantages of combining the use of laser capture microdissection (LCM) for capturing specific numbers of pure epithelial cell populations for RNA extraction, PCR amplification, and cDNA microarray analysis, as well as for confirmation of the level of gene expression by RT-PCR quantification. Our observations led us to conclude that the utilization of pure cell populations for applying genomic hierarchical cluster analysis and bioinformatics will serve in the future for patient risk assessment and for evaluating the response of the breast epithelium to chemopreventive or therapeutic agents.

References

1. American Cancer Society. *Cancer Facts and Figures 2005*. Atlanta: American Cancer Society; 2005.

2. Ghafoor, A., Jemal, A., Cokkinides, V., Cardinez, C., Murray, T., Samuels, A., Thun, M.J. Cancer Statistics for African American. *CA Cancer J. Clin.*, 52:326-341, 2002.
3. Howe HL, Wingo PA, Thun MJ, Ries LA, Rosenberg HM, Feigal EG, Edwards BK. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. *J Natl Cancer Inst.*, 93: 824-842. 2001.
4. Davis, D.L., Hoe, D., Fox, J., Lopez, A. International trends in cancer mortality in France West Germany, Italy, Japan, England and Wales, and the USA. *Lancet* 336:474- 481, 1990.
5. MacMahon, B., Cole, P., Lin, T.M. et al. Age at first birth and breast cancer risk. *Bull. Nat'l. Hlth. Org.* 43:209,1970.
6. De Waard, F. and Trichopoulos, D. A unifying concept of the etiology of breast cancer. *Int. J. Cancer* 41:666-669,1988.
7. Lambe M., C.-C. Hsieh, H.-W. Chan, A. Ekblom, D. Trichopoulos and H. O. Adami Parity, age at first and last birth, and risk of breast cancer: A population-based study in Sweden. *Breast Cancer Res. Treat.* 38: 305-311, 1996.
8. Chang J, Elledge RM. Clinical management of women with genomic BRCA1 and BRCA2 mutations. *Breast Cancer Res Treat.* 69:101-113, 2001.
9. Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. *Lancet*, 356:1876-1881, 2000.
10. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. *J Clin Oncol*; 22(6):1055-1062, 2004.
11. McGregor DH, Land CE, Choi K, Tokunaka S, Liu PI, Wakabayashi I, Beebe GW. Breast cancer incidence among atomic bomb survivors, Hiroshima and Nagasaki 1950-1989. *J Natl Cancer Inst* 59:799-811, 1977.
12. S.L. Hancock, M.A. Tucker, and R.T. Hoppe (1993). Breast cancer after treatment of Hodgkin's disease. *J. Natl. Cancer Inst.* 85:25-31. Clemons M, Loijens L, Goss P. Breast cancer risk following irradiation for Hodgkin's disease. *Cancer Treat Rev.* 26(4):291-302, 2000.
13. Pukkala, E, Auvinen, A, Wahlberg, G: Incidence of cancer among Finnish airline cabin attendants, 1967-92. *BMJ*, 311:649-52, 1995.
14. Tynes, T, Hannevik, M, Andersen, A, et al.: Incidence of breast cancer in Norwegian female radio and telegraph operators. *Cancer Causes Control*, 7:197-204, 1996.
15. Band, P.R., Le, N.D., Fang, R. Deschamps, M. Cigarette smoke and risk of breast cancer: a population-based case-control study. *The Lancet*, 360: 1033-1034, 2002.
16. Russo, I.H. Cigarette smoking and risk of breast cancer in women. *The Lancet*, 360: 1033-1034, 2002.
17. Lash TL, Aschengrau A. Alcohol Drinking and Risk of Breast Cancer. *Breast J.* 6(6):396-399, 2000.
18. Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. *Lancet*, 356:1876-1881, 2000.

19. Baum, M. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in post-menopausal women. *Breast Cancer Research and Treatment* 69(3):210, 2001.
20. Narod S. Prophylactic mastectomy in carriers of BRCA mutations. *N Engl J Med.*, 345:1498; 2001.
21. Hu, Y-F, Kaplow J, He Y. From traditional biomarkers to transcriptome analysis in drug development. *Current Molecular Medicine*, 5:29-38, 2005.
22. Russo, J. & Russo, I. Developmental pattern of the human breast and susceptibility to carcinogenesis. *European J of Cancer Prevention*. 2:85-100, 1993.
23. Russo, J. & Russo, I. Physiological basis of breast cancer prevention. *European J of Cancer Prevention*. 2:101-111,1993.
24. Russo, J., Tay, L., Russo, I. Differentiation of the mammary gland and susceptibility to carcinogenesis. *Breast Cancer Res and Treatment* 2:5-73, 1982.
25. Russo, J. & Russo, I. Biological and molecular basis of mammary carcinogenesis. *Laboratory Investigation*. 57: 112-137, 1987.
26. Russo, I., Koszalka, M., Russo, J. Human chorionic gonadotropin and mammary cancer prevention. *JNCI* 82:1286-1289, 1990.
27. Russo, I. & Russo, J. Hormone prevention of mammary carcinogenesis: a new approach in anticancer research. *Anticancer Res*. 8:1247-1264, 1988.
28. Russo, I. & Russo, J. From pathogenesis to hormone prevention of mammary carcinogenesis. *Cancer Surv*. 5:649-670,1986.
29. Srivastava, P., Russo, J. and Russo, I.H. Chorionic gonadotropin inhibits mammary carcinogenesis through activation of programmed cell death. *Carcinogenesis*, 18: 1799-1808, 1997.
30. Russo, J. & Russo, I. Toward a physiological approach to breast cancer prevention. *Cancer Epidemiology, Biomarkers and Prevention*. 3:353-364, 1994.
31. Russo, I., Koszalka, M., Russo, J. Effect of human chorionic gonadotropin on mammary gland differentiation and carcinogenesis. *Carcinogenesis*. 11: 1849-1855, 1990.
32. Russo, I. & Russo, J. Role of hCG and inhibin in breast cancer. *Int J .of Oncology* 4:297-306, 1994.
33. Srivastava, P., Russo J and Russo, I.H. Use of differential display to identify genes involved in the prevention of mammary tumorigenesis. *Proc. Differential Display and Related Techniques for Gene Discovery*, Cold Spring Harbor, New York, October, 1996. P117.
34. Mailo D, Russo J, Sheriff F, Balogh G, Heulings R, Russo IH. Specificity of the Genomic Signature of Human Chorionic Gonadotropin in its Preventive Effect on Mammary Carcinogenesis. *Proc. Am. Assoc. Cancer Res.*2005.
35. Wang R, Mailo D, Russo J, Sheriff FS, Fernbaugh R, Russo P, Moral R, Russo IH. The preventive effect of hCG is associated with a specific genomic signature in the rat mammary gland. *Proc. Am. Assoc. Cancer Res*. 2005.
36. Srivastava, P., Russo, J., Russo, I.H. Chorionic gonadotropin induces programmed cell death in the rat mammary gland. *Proc. Am. Assoc. Cancer Res*. 37: 98a, 1996.
37. Tahin, Q., Mgbonyebi, O.P., Russo, J. and Russo, I.H. Influence of hormonal changes induced by the placental hormone chorionic gonadotropin on the progression of mammary tumorigenesis. *Proc. Am. Assoc. Cancer Res*. 37: 1622a, 1996.

38. Srivastava, P., Russo, J., Estrada, S., and Russo, I.H. P53 and cyclins A and D regulate the inhibition of tumor progression induced by chorionic gonadotropin. *Proc. Am. Assoc. Cancer Res.* 37: 2a, 1996.
39. Srivastava, P., Russo, J. and Russo, I.H. Inhibition of rat mammary tumorigenesis by human chorionic gonadotropin is associated with increased expression of inhibin. *Mol. Carcinog.* 26: 10-19, 1999.
40. Alvarado, M., Alvarado, N., Russo, J., Russo, I. Human chorionic gonadotropin inhibits proliferation and induces expression of inhibin in human breast epithelial cells in vitro. *In Vitro* 30A:4-8, 1994.
41. Srivastava, P., Silva, I.D.C.G., Mgbonyebi, P., Russo, J., and Russo, I.H. Identification of genes differentially expressed in human breast carcinoma cells treated with human chorionic gonadotropin. *Proc. Am. Assoc. Cancer Res.* 39: 777a, 1998.
42. Russo, J., Janssens, J., Russo, I.H. Recombinant human chorionic gonadotropin (r-hCG) significantly reduces primary tumor cell proliferation in patients with breast cancer. *Breast Cancer Res. Treat.*, 64: 51 (161a), 2000.
43. Carne, S. The action of chorionic gonadotropin in the obese. *Lancet* 2:1307, 1961.
44. Kliesch, S., Behre, H., Nieschlag, E. High efficacy of gonadotropin or pulsatile gonadotropin-releasing hormone treatment in hypogonadotropic hypogonadal men. *Eur. J. Endocrinol.* 131:347-354, 1994.
45. Quenby, M, Farquharson, R. Human chorionic gonadotropin supplementation in recurring pregnancy loss: a controlled trial. *Fertil. Steril.* 62:708-710, 1994.
46. Wrensch, et al. Breast cancer incidence in women with abnormal cytology in nipple aspirates of breast fluid. *Am. J. Epidemiology* 135:130-141, 1992.
47. Dooley, W., Ljung, B., Veronesi, U., Cazzaniga, M., Elledge, R., O'Shaughnessy, JA, Kuerer HM, Hung DT, Khan SA, Phillips RF, Ganz PA, Euhus DM, Esserman LJ, Haffty BG, King BL, Kelley MC, Anderson MM, Schmit PJ, Clark RR, Kass FC, Anderson BO, Troyan SL, Arias RD, Quiring JN, Love SM, Page DL, King EB. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. *J Natl Cancer Inst*, 93:1624-1632, 2001.
48. Dooley WC, Veronesi U, Elledge R, O'Shaughnessy J, Ljung B, Arias R. Detection of premalignant and malignant breast cells by ductal lavage. *Obstet Gynecol.*, 97(4Suppl 1):S2, 2001.
49. Evron E, Dooley WC, Umbricht CB, Rosenthal D, Sacchi N, Gabrielson E, Soito AB, Hung DT, Ljung B, Davidson NE, Sukumar S. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. *Lancet*, 357:1335-1336, 2001.
50. Patriotis PC, Querec TD, Gruver BN, Brown TR, Patriotis C. ArrayExplorer, a program in Visual Basic for robust and accurate filter cDNA array analysis. *Biotechniques.* 31(4): p.862-872,2001
51. Querec TD, Gruver BN, Patriotis PC, Stoyanova R, Frolov AE, Engstrom PF, Godwin AK, Brown TR, and Patriotis C. Differential gene expression patterns associated with the in vitro malignant transformation of human ovarian epithelial cells and chemopreventive treatment with Fenretidine. In 92nd Annual Meeting of the American Association for Cancer research. 2001. New Orleans, LA: Cadmus Journal Services, Linthicum, MD.
52. Berggren K, Chernokalskaya E, Steinberg TH, Kemper C, Lopez MF, Diwu Z, Haugland RP, Patton WF. Background-free, high sensitivity staining of proteins in one- and two-dimensional sodium dodecyl sulfate-polyacrylamide gels using a luminescent ruthenium complex. *Electrophoresis.* 2000. 21(12): p. 2509-21.

53. Steinberg, T.H. et al., Ultrasensitive fluorescence protein detection in isoelectric focusing gels using a ruthenium metal chelate stain. *Electrophoresis*, 2000. 21(3): p. 486-96.
54. Berggren, K. et al., A luminescent ruthenium complex for ultrasensitive detection of proteins immobilized on membrane supports. *Anal Biochem*, 1999. 276(2): p. 129-43.
55. Basolo, F., Elliott, J., Tait, L., Chen, X.Q., Maloney, T., Russo, I.H., Pauley, R., Momiki, S., Caamano, J., Klein-Szanto, A.J.P., Koszalka, M. and Russo, J. Transformation of Human Breast Epithelial Cells by c-Ha-ras oncogene. *Molecular Carcinogenesis*, 4:25-35, 1991.

List of Personnel

Irma Russo, M.D. – Principal Investigator
Jose Russo, M.D. – Co-Investigator
Mufei Liu, Ph.D. – Postdoctoral Associate
Edward Sauter, M.D. – Former Principal Investigator

Appendix

Russo, I.H., Wang, R., Balogh, GA, Sheriff, F. Masny, A., Daly, MB, Torosian, M., Russo, J. IDENTIFICATION OF MOLECULAR BIOMARKERS OF CANCER RISK IN CYTOLOGICALLY NORMAL BREAST EPITHELIAL CELLS. Era of Hope meeting in Philadelphia, Pennsylvania, June 8-11, 2005.

Appendix

Russo, I.H., Wang, R., Balogh, GA, Sheriff, F. Masny, A., Daly, MB, Torosian, M., Russo, J. IDENTIFICATION OF MOLECULAR BIOMARKERS OF CANCER RISK IN CYTOLOGICALLY NORMAL BREAST EPITHELIAL CELLS. Era of Hope meeting in Philadelphia, Pennsylvania, June 8-11, 2005.

Women who are carriers of BRCA/BRCA2 mutations may have a lifetime risk of breast cancer as high as 85%. Even though it is known that BRCA1 mutation carriers are more likely to develop tumors that are estrogen receptor negative, being less likely to benefit from antiestrogen chemopreventive treatments, currently it is not possible to predict who will actually develop breast cancer. The use of molecular approaches will allow us to identify the "high risk" genomic signature of the cytological normal breast epithelium of women at high risk for breast cancer. This signature will serve as an intermediate biomarker for evaluating the response of the breast to novel chemopreventive agents.

For this purpose we analyzed pure epithelial cell populations obtained by laser capture microdissection (LCM) utilizing cytological smears of the normal human breast epithelial cell line MCF-10F. We captured 20, 200, and 2000 cells. RNA from each set of cells was extracted with a commercially available RNA isolation kit. Cells were mixed with 20 μ l of RNA extraction buffer and incubated at 42°C for 30 min. Purified RNA was measured by fluorometric quantitation and a linear RT-PCR assay developed in our laboratory. In order to obtain 20-40 μ g RNA needed for microarray analysis, RNA was amplified using linear and PCR amplification. The housekeeping gene 18S was utilized for generating a standard curve. Concentrations of 18S gene were compared with those of the breast epithelium specific genes fat milk globule membrane antigen and whey acidic protein.

Our results led us to conclude that RT-PCR is sensitive for detecting RNA from small numbers of LCM selected cells, being able to detect few copies of RNA, whereas the amounts of RNA obtained by linear amplification did not suffice for its use in microarray analysis. These observations confirmed the usefulness of the application of LCM to cytospin preparations for obtaining pure cell populations for RNA extraction and of PCR RNA amplification for cDNA microarray analysis and of RT-PCR for gene expression level quantification. The possibilities of using a minimal number of cells and the utilization of RT-PCR instead of linear amplification for obtaining RNA in adequate amount and quality for performing cDNA microarray analysis represented a significant step to warrant that the breast epithelial cells from selected donors can be studied in the same fashion. These studies will lead to fruitful results through genomic hierarchical cluster analysis and bioinformatics for patient risk assessment. This meeting offers a great opportunity to scientists and health care providers of discussing with consumers and the general public affected by breast cancer the potential of this approach for assessing risk using molecular biomarkers.